Iran (Islamic Republic of) vs Slovenia: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Iran (Islamic Republic of)
54.0%
in 2025
Slovenia
55.0%
in 2025
Iran (Islamic Republic of) rank
151st
Slovenia rank
150th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Iran (Islamic Republic of)
- Slovenia
How they compare
Slovenia currently reports 55.0% against 54.0% in Iran (Islamic Republic of), a difference of 1.0%.
Across all 18 years both countries report, Slovenia has been ahead every year.
Iran (Islamic Republic of) ranks 151st and Slovenia ranks 150th of 192 countries.
Slovenia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Iran (Islamic Republic of) | Slovenia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 0.0% | 28.0% | 28.0% | Slovenia |
| 2020s | 9.0% | 59.7% | 50.7% | Slovenia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Iran (Islamic Republic of) or Slovenia?
- Slovenia, at 55.0% against 54.0% in Iran (Islamic Republic of) as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Iran (Islamic Republic of) and Slovenia?
- 1.0%, with Slovenia ahead.
- How many years of comparable data are there for Iran (Islamic Republic of) and Slovenia?
- 18 years are reported by both, from 2008 to 2025.
- How do Iran (Islamic Republic of) and Slovenia rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Iran (Islamic Republic of) ranks 151st and Slovenia ranks 150th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.